Edition:
United States

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

18.53USD
20 Apr 2018
Change (% chg)

$0.68 (+3.81%)
Prev Close
$17.85
Open
$17.90
Day's High
$19.06
Day's Low
$17.84
Volume
200,333
Avg. Vol
153,195
52-wk High
$31.91
52-wk Low
$8.10

Select another date:

Wed, Mar 14 2018

BRIEF-Voyager Therapeutics Reports Q4 GAAP Loss Per Share $0.40

* VOYAGER THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease

* VOYAGER THERAPEUTICS ANNOUNCES LONGER-TERM DATA FROM ONGOING PHASE 1B TRIAL OF VY-AADC FOR ADVANCED PARKINSON’S DISEASE

BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration

* VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP POTENTIAL NEW TREATMENTS FOR ALZHEIMER’S DISEASE AND OTHER TAU-RELATED NEURODEGENERATIVE DISEASES

BRIEF-Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC

* VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE

BRIEF-Ophthotech Announces Election Of Jane Pritchett Henderson, CFO And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors

* OPHTHOTECH ANNOUNCES ELECTION OF JANE PRITCHETT HENDERSON, CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT AT VOYAGER THERAPEUTICS, TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics

* BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING‍​ Source text: (http://bit.ly/2CZEeZD) Further company coverage:

BRIEF-Voyager Therapeutics prices public offering of 4.50 mln common shares at $12/shr

* Voyager Therapeutics announces pricing of public offering of common stock

BRIEF-Voyager Therapeutics announces proposed offering of common stock

* Voyager Therapeutics announces proposed offering of common stock

BRIEF-Voyager Therapeutics reports Q3 GAAP loss per share $0.89

* Voyager Therapeutics Inc reports third quarter 2017 financial results and corporate highlights

Select another date: